Human xenografts for microbicide testing and anatomical modeling

ABSTRACT

A method for screening candidate antimicrobial compounds is described that utilizes a human vaginal xenograft engrafted in a non-human host. The method may be performed by using pathogen inoculated human vaginal xenografts in order to screen a wide range of candidate antimicrobials administered topically or systemically.

This is a Divisional application which claims priority to pending U.S.patent application Ser. No. 09/426,144 filed on Oct. 22, 1999.

FIELD OF THE INVENTION

The present invention relates generally to the incorporation of humantissue xenografts into methods for modeling the physiology and anatomyof vaginal epithelium, studying fastidious vaginal pathogens, evaluatingthe pharmacology of vaginally reactive agents, and, in particular,evaluating the efficacy of candidate anti-microbial agents and, moreparticularly, to screening the capacity of candidate microbicides, inhuman vaginal xenografts, to prevent and/or treat sexually transmitteddiseases.

BACKGROUND OF THE INVENTION I. Sexually Transmitted Diseases

Sexually transmitted diseases (STDs), referring to diseases that aremost often transmitted by direct sexual contact, remain an increasinglyserious public health problem in the United States, as well as othercountries. Indeed, these diseases present a public health crisis. Seee.g., Herold et al., Antimicrob. Agent. Chemother., 41:2776-278 (1997).For Example, according to the Summary of Notifiable Diseases, five ofthe ten most prevalent infectious diseases are STDs. Summary ofNotifiable Diseases—United States, 1996. MMWR Morb. Mortal. Wkly. Rep.p. 45 (1997). Additionally, The World Health Organization has estimatedthat 125 million new cases of major bacterial and viral STDs occur eachyear (See, Herold, supra, at p. 2776). In terms of human cost, the WorldBank has estimated that for adults of 15 to 44 years of age, STDs (otherthan human immunodeficiency virus (HIV) infection) are the secondleading cause of healthy life lost in women (See, Herold, supra, at p.2776). Women are especially at risk as many STDs are asymptomatic andthere is a high morbidity rate associated with untreated disease (Seee.g., Biro et al., Clin. Pediatr., 33:601-605 [1994]). Of thesediseases, significant etiologic agents are human papillomavirus (HPV),herpes. simplex virus type 2 (HSV-2), HIV, Chlamydia trachomatis,Neisseria gonorrhloeae, and Treponema pallidum.

A. Human Papillomavirus

Human papillomaviruses are a heterogeneous group of viruses that induceepithelial or fibroepithelial proliferations of skin or mucosa. Over 80types of human papillomavirus (HPV) are recognized, many of which areassociated with distinctive lesions. Specific diseases associated withHPV infection, such as common warts, epidermodysplasia verruciformis,and genital warts (condylomata), correlate with specific HPV types. Forexample, HPV-1 has been shown to produce skin warts, and HPV-11 has beenshown to produce genital warts. The latter type can also produce wartson the vocal cords of newborns who have been infected by their mothers.Such warts are a serious problem to the newborns because they maythreaten breathing and must be surgically removed.

Recent studies have implicated HPVs in the development of premalignantand malignant lesions of the skin (Ikenberg et al., Int. J. Cancer, 32:563-565, 1983; Orth et al., Cancer Res., 39: 1074-1082, 1979), uterinecervix (Durst et al., Proc. Natl. Acad. Sci., 80: 3812-3815, 1983), andlarynx (Galloway et al., Arch. Otol., 72: 289-294, 1960). For example,HPV-16 and HPV-18 has been isolated and molecularly cloned from cervicalcarcinoma cells and these HPV types are strongly associated withcervical carcinomas. It is significant to note that HPV's only grow indifferentiating human epithelium. Notably, methods of propagating anddetecting HPV have been described in U.S. Pat. Nos. 4,814,268 and5,071,757 hereby incorporated by reference.

B. HIV

Since its recognition in 1981, the acquired immunodeficiency syndrome(AIDS) has become a catastrophic pandemic. The worldwide prevalence ofthe human immunodeficiency virus (HIV) infection has been estimated atmore than 30,000,000. In addition, an estimated of 1.5 million childrenhave been infected with HIV (Famighetti, 1996 World Almanac and Book ofFacts, World Almanac Books, Mahwah, N.J., [1995], p.840). In 1996, theincidence of AIDS-opportunistic illnesses in the United States, wasapproximately 6,390 per 100,00 population for those 50 years of age andolder; for those 13-49 years of age, the incidence was approximately50,340 per 100,000 (“AIDS Among Persons Aged ≧50 Years—United States,1991-1996,” Morbidity and Mortality Weekly Report, Jan. 23, 1998). TheAIDS pandemic is a premiere public health concern. Individuals who areat high risk of HIV infection are also at risk of infection by othersexually transmitted pathogens. Similarly, individuals at risk fornon-HIV sexually transmitted pathogens are also at high risk for HIVinfection.

Additionally, it is significant to note that women comprise the mostrapidly increasing population of the AIDS epidemic. Furthermore, thesite of HIV entry (e.g., vagina, cervix, etc) in women is poorlydefined. Therefore, protection of vaginal and anal epithelium from HIVentry [beyond the current questionable effective and often irritatingapplication of Nonoxynol-9 (N-9)] is desirable.

C. Chlamydia Trachomatis

Considering epidemiological data for C. trachomatis, the reported numberof cases in the U.S. for 1996 was 490,000 (i.e., a rate of 194.5 per100,000 persons (this rate was based on reports from 49 states, and theDistrict of Columbia, although only cases from New York City areincluded in the figures for New York). See, Division of STD Prevention,Sexually Transmitted Disease Surveillance, 1996, U.S. Department ofHealth and Human Services, Public Health Service, Centers for DiseaseControl and Prevention, September, 1997. This rate exceeds that of allother notifiable infectious diseases in the U.S. This represents anincrease from 47.8 per 100,000 to 194.5, for the time period of 1987 to1996. For the period of 1995 to 1996, the rates increased 2% (i.e., from313.2 cases per 100,000 to 318.6). For women, the rate (321.5 per100,000) was over five times that reported in men. In terms of thefemale population infected, the highest rates of chlamydia infectionoccurred in adolescents. The rates are highest in the 15 to 19 year oldpopulation with 2,068.6 cases per 100,000, followed by the 20 to 24 yearold age group, with 1,485.2 cases. In addition, the prevalence of C.trachomatis infection is highest in economically disadvantaged youngwomen. Untreated C. trachomatis infections often present debilitatingsequelae such as pelvic inflammatory disease (PID), which can lead toinfertility, ectopic pregnancy, and chronic pelvic pain.

D. HSV-2

Herpes simplex virus 2 (HSV-2) causes a significant amount of morbidityand mortality. The prevalence of HSV-2 infection increases atadolescence, with infection rates of 15 to more than 50% in some adultpopulations (See e.g., Arvin and Prober, “Herpes Simplex Viruses,” inMurray et al. (eds.), Manual of Clinical Microbiology, (6th ed.), ASMPress, Washington, D.C., pages 876-883 [1995]; Rosenthal et al., Clin.Infect. Dis., 24:135-139 [1997]; and Stanberry, Understanding Herpes,University Press of Mississippi, Jackson, Miss. [1998]).

Many cases of HSV-2 infection are subclinical. Indeed, primaryinfections are often entirely asymptomatic. In addition, despite theapparently universal establishment of latency following infection witheither virus, many individuals with past HSV infections do notexperience symptomatic recurrences. However, asymptomatic recurrences dooccur, making prevention of the transmission HSV-2 in the populationvery difficult. Indeed, HSV-2 infections may cause acute, latent, andrecurrent genital infections. In immunocompromised patients, the lesionsassociated with HSV-2 may be severe. In addition, infected pregnantwomen may shed HSV-2, thereby (at times) fatally infecting theirnewborns.

E. Neisseria gonorrhea

In the United States alone, conservative estimates suggest that aboutone million people per year are infected with N. gonorrhea. Worldwide,there is an estimated annual incidence of 25 million cases of N.gonorrhoeae (Crotchfelt et al., J. Clin. Microbiol., 35:1536-1540[1997]). Although the number of gonorrhea cases has steadily decreasedsince the establishment of gonorrhea control programs in the mid-1970s,the problem is not solved. Gonorrhea remains a significant cause ofmorbidity. Infection with N. gonorrhoeae remains a major case of PID,tubal infertility, ectopic pregnancy, and chronic pelvic pain.Furthermore, epidmiologic evidence strongly suggest that gonococcalinfections facilitate HIV transmission. Rates of gonorrhea in women areparticularly high in adolescents, with the highest rates observed in 15to 19 years olds. For men, the highest rate was observed in the 20 to 24year old age group. In addition, the percentage of men with repeatedinfection within a one year period has increased from a low of 13.8% in1994, to 15.7% in 1996. Of additional concern is the growing number ofN. gonorrhoeae isolates with decreased susceptibility to penicillinand/or tetracycline, and ciprofloxacin.

Although there has been considerable work on N. gonorrhoeae vaccines,none are available. In the case of gonorrhoea, it is unlikely that avaccine will be easily developed because of the rapid and effectiveantigenic modulation which is one of the hallmarks of N. gonorrhoea(Phillips, Perspect. Drug Disc. Design 5:213-224 [1996]).

F. Treponema pallidum

Infection with Treponema pallidum, the etiologic agent of syphilis is ofparticular concern during pregnancy, as untreated early syphilis resultsin perinatal death in up to 40% of cases. If the syphilitic infection isacquired during the four years prior to pregnancy, the fetus is infectedin over 70% of cases. Furthermore, syphilis facilitates transmission ofHIV and may be particularly significant in areas of the United States(e.g., the South), where both infection rates are high.

In sum, clinical pathologies attributable to STDs are profound. STDscause acute and chronic disease, infertility, and (in some cases)cancer. Vaccines, which are costly and time-consuming to develop, areunavailable for the treatment of most STDs. This is especially true inthe case of HIV where the absence of a vaccine has necessitated theemploy of alternative therapeutic strategies, such as retrovirus tripletherapy (e.g., AZT, DDI, etc.) to lower virus burden. However, it costsapproximately $15,000 (U.S.) annually to maintain a patient onretrovirus triple therapy. This expense, therefore, renders thistherapeutic option practically unavailable to Third World populationswhere HIV is most prevalent. Indeed, the sum of all available STDtherapeutics is effective against only a limited number of susceptiblepathogens. Furthermore, this limited therapeutic arsenal is largelyconfined to proprietary formulations which are costly for the afflictedto procure.

II. Antimicrobial Agents

Antimicrobial agents act according to a variety of mechanisms.Specifically, these agents may destroy microbes, prevent theirpathogenic action, or inhibit their growth. Antimicrobial agents, oftenreferred to as anti-infective agents, are conveniently applied topicallyto the skin and mucous membranes. In some instances antimicrobial agentsmay be incorporated into pharmaceutical preparations suitable forintravaginal administration. Regardless of the formulation, however,desirable properties of antimicrobial agents include, but are notlimited to, properties recited in Table 1.

TABLE I Ideal Properties For A Candidate Antimicrobicide Broad SpectrumAble to inactivate bacteria and viruses and possibly fungi Fast ActingAble to be effective within minutes of application Persistent Effectiveafter initial application long enough to allow discreet insertion by thefemale; capable of being effective for more than one coitus during asingle encounter Inexpensive Affordable to the poor and inhabitants ofthe Third World Easy to Formulate Stable at ambient temperature;compatible and active after mixture with chemically simple andcosmetically acceptable formulations Non-Toxic Non-damaging to vulvar,vaginal, cervical or penile epithelium and possibly non-damaging tosperm; does not facilitate entry of STDs, allows survival of beneficialLactobacilli sp. Discreet Undetectable, or at least innocuous, in orderto avoid resistance to use by women or their partners.

Topical antimicrobial agents may be directed at bacteria, viruses,fungi, and parasites (including-but not limited to Trichomonavaginalis). Topical antimicrobial agents are convenient for vaginalapplication and have been successfully employed in the prevention andtreatment of a number of infections including some STDs. N-9,specifically, inactivates enveloped viruses such as HSV-2 and HIV-1 invitro. Hicks, R. R., et al., “Inactivation of HTLV-III/LAV-infectedcultures of normal human lymphocytes by nonoxynol-9 in vivo.”, Lancet,2(8469-8470):1422-1423, (1985), Rapp, F. et al, “Synergistic effect ofhuman leukocyte interferon and nonoxynol-9 against herpes simplex virustype 2.” Antimicro. Agnt. and Chemo., 28:449-451, (1985) and Judson, F.N., et al.,“In vitro evaluations of condoms with and without nonoxynol-9as physical and chemical barriers against Chlamydia trachomatis, herpessimplex virus type 2 and human immunodeficiency virus.” Sex. Trans. Dis.16:51-56, (1989). However, N-9 has not been proven to preventtransmission to women of some of the most deadly STDs, most notably,HIV. Roddy, R. E., et al., “A controlled trial of nonoxynol-9 film toreduce male-to-female transmission of sexually transmitted diseases.” N.Engl. J. Med. 339(8):504-10, (1998). Additionally, N-9 may causeirritation and ulceration in some people, thereby increasing STDsusceptibility via trans-ulcer inoculation of pathogens or by increasingthe number of proliferative cells in regenerative hyperplasia. Kreiss,J., et al., “Efficacy of nonoxynol-9 contraceptive sponge use inpreventing heterosexual acquisition of HIV in Nairobi prostitutes.” JAMA268 (4):477-482 (1992). Finally, N-9 does not inactivate HPVs and,therefore, does not qualify as an antiviral microbicide vis-a-vis HPV.

In another example, C31G is an amphoteric, surface-active agent that iseffective in vitro against a broad range of viral and bacterialpathogens. Calis, S., et al. “A non-antibiotic antimicrobial mixture(C31G): evaluation of the antimicrobial efficiency of C31G on vaginalcultures.”, Boll. Chim. Farmaceut. 131:335-338 (1992), Corner, A. M., etal., “C31G, a new agent for oral use with potent antimicrobial andantiadherence properties.” Antimicro. Agents Chemo. 32:350-353, (1988).C31G, however, is not effective against Human Papillomavirus (HPVs).

III. Existing Models For Screening STD Susceptibility To Microbicides

Currently available in vivo models for evaluating microbial efficacy arelimited. HSV-2 has been propagated through inoculation into the mousevagina. However, in the case of fastidious viruses, such as HIV and HPV,animal models for STDs are restricted to primates. Fastidious viruseshave also been propagated in human tissue transplanted into non-humanhosts, namely immunocompromised mice (e.g., the renal capsule). See U.S.Pat. Nos. 4,814,268 and 5,071,757 to Kreider et al. However, this priorart does not provide an experimental platform that mimics the true threedimensional architecture of human vagina in situ. Furthermore, since theprior art implants chips of human tissue to the renal capsule of anon-human host; any direct post-transplant manipulation or treatment ofsaid chips requires traumatic surgical invasion into the peritoneum ofsaid non-human host.

SUMMARY OF THE INVENTION

The present invention relates generally to the incorporation of humantissue xenografts into methods for evaluating the efficacy of topical orsystemic candidate anti-microbial compounds and, in particular, toscreening the capacity of candidate microbicides, in human vaginalxenografts, to prevent and/or treat sexually transmitted diseases.

Specifically, human vaginal xenografts have a complement of morphologicand cytochemical characteristics that are topolographically similar tonormal vagina. These characteristics include (but are not limited to)glycogen production, the elaboration of both estrogen receptors (ER) andprogesterone receptors (PR) as well as lactoferrin (LF) production.Additionally, these xenografts elaborate glutamyl cysteine synthesis(GCS), glutathione-S-transferases (GST) and Mn and Cu/Zn superoxidedismutases (SOD) which are enzymes, found in situ in vaginal tissue,that protect vaginal epithelial cells from reactive oxygen species(ROS). By creating vaginal xenografts with such physiological andanatomical parameters of those of native in situ vaginal tissue, drugscan be evaluated against the relevant tissue architecture. This confersadvantages to the screening methods claimed through the instantinvention. Most importantly, the in situ growth of human tissue permitsthe propagation of pathogens unable to be propagated (e.g., humanpapillomavirus) in cell culture.

The present invention provides methods for configuring vaginal tissueremoved from a human source under conditions such that a lumen iscreated. The present invention also recites methods for engrafting humanvaginal tissue into a non-human host such that said human xenograft issustained by the internal milieu of said non-human host. The engraftedhuman vaginal tissue provides a stable platform that is not rejected bythe non-human host and the vaginal tissue does not necrose.

The present invention also contemplates anal epithelium, removed from ahuman source, configured to create a lumen substantially lined withepithelium. The present invention also recites methods for engraftingsaid anal epithelium comprising a lumen into a non-human host such thatsaid human xenograft is sustained by the internal milieu of saidnon-human host. The engrafted human anal tissue provides a stableplatform that is not rejected by the non-human host and the anal tissuedoes not necrose.

Methods employed to facilitate the maintenance of human xenografts in anon-human host include (but are not limited to) the use of animmunocompromised animal and the supplementation of said animal withtrophic factors including (but not limited to) gonadal hormones. It isnot intended the present invention be limited to any specificimmunocompromised non-human host. In one embodiment, theimmunocompromised host may be produced through breeding animals withgenetic defects. While it is not intended that the present invention belimited to any specific immunocompromised host, in one example theimmunocompromised hosts are athymic mice and SCID (severe combinedimmune deficiency syndrome) mice. In another embodiment, normal animalswith no somatic deficiency may be treated systemically (e.g. withelectromagnetic radiation, anti-sera, or chemical agents) to render saidtreated normal animals immunocompromised. In another embodiment, normalanimals with no somatic deficiency may be treated surgically to rendersaid treated normal animals immunocompromised. In another embodiment,normal animals may be treated with cyclosporin or otherimmunosuppressive agents to render said animals immunocompromised.

The present invention also provides methods for the topical or systemictreatment of said engrafted human vaginal tissue with candidateantimicrobial compounds. It is not intended that screening methods ofthe instant invention be limited to any specific class of candidateantimicrobial compounds. Examples of said candidate antimicrobialcompounds include (but are not limited to) detergents, surfactants,alcohols, antibiotics, antibodies, small peptide microbicides, andprotein denaturants.

The present invention also provides methods for the inoculation of humanvaginal tissue (both untreated and previously treated with candidateantimicrobial compounds) and the subsequent evaluation of saidinoculated engrafted tissue for the transmission and infection of saidsexually transmitted pathogens and, thereby, the efficacy of saidcandidate antimicrobial compounds.

In one embodiment, the present invention contemplates a method forscreening chemical compounds comprising: a) providing, in any order: i)a non-human host; ii) a human vaginal graft comprising a lumen; iii) acandidate compound; and iv) a pathogen; b) engrafting said vaginal graftwithin said host to create an engrafted vaginal xenograft comprising alumen; c) introducing said compound into said non-human host viaapplication methods selected from topical application and systemicadministration; d) inoculating said engrafted vaginal xenograft withsaid pathogen; and e) testing said engrafted vaginal xenograft for thepresence of pathogen. It is not intended that the present invention belimited by the antimicrobial mechanism of any candidate antimicrobialcompound.

DESCRIPTION OF THE FIGURES

The file of this patent contains at least one drawing executed in color.Copies of this patent with color drawings will be provided by the Patentand Trademark Office upon request and payment of the necessary fee.

FIG. 1 presents a schematic overview of the steps comprising thescreening methods recited in the instant invention including; humanvaginal xenograft engraftment, graft infection, and assay for residualinfectivity in said human vaginal xenografts.

FIG. 2 presents photomicrographs from premenopausal vaginal tissue(controls) and xenografts stained for glycogen by Periodic Acid Schiff(PAS) and immunostained for ER or PR.

FIG. 3 presents photomicrographs (at 40X) of tissue sections frompremenopausal vaginas (C), and vaginal xenografts (X) immunoreacted forLF, surfactant protein A (SP-A), catalase and SOD.

FIG. 4 presents photomicrographs of harvested grafts which receivedSodium Dodecyl Sulfate (SDS)-treated virus (panels a, b and c) oruntreated virus (panels d, e, and f). Panels a and d representhematoxylin and eosin stained tissues, panels b and e show hybridizationof HPV-11 DNA probe and panels c and f show GSA staining for HPVprotein.

FIG. 5 presents illustrative values of mean estrogen and progesteronelevels at various stages of the menstrual cycle.

DEFINITIONS

To facilitate understanding of the invention set forth in the disclosurethat follows, a number of terms are defined below.

As used herein the term “antimicrobial compound” is used in reference toany compound, substance, or molecule capable of inhibiting the growthof, or of killing microorganisms (e.g., showing activity in vitro or invivo). It is intended that the term be used in its broadest sense, andincludes, but is not limited to compounds such as antibiotics which areproduced naturally or synthetically. It is also intended that the terminclude compounds and elements that are useful for inhibiting the growthof, or killing, microorganisms. It is contemplated that compositionscontaining multiple compounds will find use in the present invention.For example, it is intended that the term encompass antimicrobialcompositions in which a given compound is included as a component inaddition to other compounds. It is not intended that the presentinvention be limited to any particular antimicrobial composition.

As used herein the term “candidate antimicrobial compound” is a compoundsuspected of having antimicrobial properties

As used herein the term “candidate compound” is a compound of unknownantimicrobial properties.

As used herein the term “fastidious virus” is used in reference to avirus which is difficult or impossible to propagate in vitro or inlaboratory animal hosts. An example of said fastidious viruses includes,but is not limited to, HPV.

As used herein the term “in situ vaginal tissue” is used in reference tothe morphological and physiological profile of human vaginal tissueunencumbered by detectable anatomical abnormalities or disease states.

As used herein the term “isolated” in the context of tissue indicatestissue removed and/or separated from its natural source. A tissue graftis one embodiment of isolated tissue that has been transplanted.

As used herein the term “sexually transmitted pathogen” refers topathogens that are most often transmitted by direct sexual contact,including kissing and vaginal intercourse, as well as anal intercourse,and other sexual activities. The term encompasses, but is not limitedto, such diseases as HIV, Chlamydia trachomatis, human papillomavirus(HPV), herpes simplex virus, Neisseria gonorrhea, and Treponemapallidum.

As used herein the term “systemic” or “systemically” refers to theintroduction of a compound into the circulatory or lymphatic system

As used herein the term “topically” means application to the surface ofthe skin, mucosa, viscera, etc of a target tissue.

As used herein the term “split-thickness graft” refers to part of theepithelium and subjacent stroma.

As used herein the term “engrafted” refers to tissue surgicallyimplanted at any anatomical site under conditions such that the internalmilieu of the host may sustain said tissue.

As used herein “pharmaceutical preparation suitable for intravaginaladministration” refers to a solution containing a desired compound in apharmaceutically acceptable form for intravaginal administration. Thepharmaceutical preparation may contain diluents, adjuvants andexcipients, among other components, provided that those additionalcomponents neither adversely effect the preparation (e.g., they do notcause degradation of the compound) nor the recipient (e.g., they do notcause a hypersensitivity reaction).

As used herein “Nonoxynol-9” or “N-9” refers to a nonionic surfactant,in some applications, topically applied as a spermicide.

As used herein “Immunocompromised” refers to an animal with an immunesystem rendered deficient (as compared to a normal control animal) by animmunodeficiency disorder or by the administration immunosuppressiveagents or electromagnetic radiation.

As used herein a “Challenged Graft” refers xenobiotic tissue contactedwith one or more pathogens said pathogens (in some but not allembodiments) having already been contacted with a candidate compound.

DESCRIPTION OF THE INVENTION

The present invention relates to human xenografts in animals and methodsfor evaluating the efficacy of topically and systemically appliedcompounds as microbicides. These engrafted xenografts are intended to bephysiologically stable platforms capable of propagating a host ofsexually transmitted pathogens including, but not limited to, fastidiousviruses such as HPVs. Such a susceptible platform is a component of themethods for screening candidate antimicrobial compounds. A schematicoverview of said methods for screening is presented in FIG. 1.

The description of the invention is divided into the following parts: I)Construction of Human Vaginal Xenograft And Implantation Into a AnimalHost, II) Application Of Candidate Microbicides, III) Infection Of HumanVaginal Xenografts With Pathogens, IV) Detecting Pathogens In PathogenInoculated Human Vaginal Xenografts.

I. Construction Of Human Vaginal Xenografts And Implant Into An AnimalHost

A. Graft Construction

The instant invention contemplates the use of human vaginal tissue in amethod for the screening the antimicrobial activity of topically orsystemically applied chemical compounds. In a preferred embodiment, saidhuman vaginal tissue is conveniently obtained from surgical specimensremoved during vaginal reconstructive surgeries. Tissue may also beobtained from post-mortem specimens. In one example, said tissue isobtained from the surgical repair of a vaginal prolapse. Regardless ofthe source, however, sections of split-thickness vaginal epithelium arecut from vaginal wall specimens. In one embodiment, the vaginal wallspecimens are trimmed to a piece 2 cm wide ×2 cm long ×0.5 mm thick.Said vaginal wall specimens are fashioned into a rolled graft, therebycreating a lumen, such that said lumen is surrounded by the epithelialsurface of the source vaginal tissue. The construction of said rolledgraft comprising a lumen may be accomplished with suturing. However, ina preferred embodiment, a sutureless rolled graft is created whichminimizes mechanical damage thereby creating a superior experimentalplatform.

Although the engraftment site of the graft is not limited to anyspecific anatomical site, in one embodiment, the rolled graft (with orwithout sutures) is inserted into the subcutaneous space on the back ofan anesthetized immunocompromised mouse and the skin wound is closedwith a wound clip. Xenografts are allowed to heal into the subcutaneousspace. Testing, treatment and/or infection of such grafts can beinitiated at the time of grafting or at a subsequent time pointdepending on the desired experimental protocol.

B. Selection of an Animal Host and Introduction of a Human Graft

i. Selection of an Animal Host

It is not intended that the instant invention be limited by the genus orspecies of the non-human host. However, it is preferred that the host beimmunocompromised. A variety of non-human animals can be used as thegraft recipient, including but not limited to vertebrates such asrodents, non-human primates, ovines, bovines, ruminants, lagomorphs,porcines, caprines, equines, canines, felines, aves, etc. Preferrednon-human animals are selected from the rodent family including rat andmouse, most preferably mouse. The following commercially availableimmunocompromised animals are preferred:

1. Athymic female mice, 3-4 weeks of age, available from Taconic Farms(Germantown, N.Y.).

2. SCID (severe combined immune deficiency syndrome) female mice, 3-4weeks of age, available from Charles River (Wilmington, Mass.).

Athymic or SCID mice will tolerate the long-term growth of xenogenictissues especially well. The mice are immunologically deficient andallow long-term (over 1 year) survival of the xenografts. Nonetheless,other animals are also contemplated, such as animals that have beenirradiated, surgically altered, or subjected to chemical treatments suchthat nascent immune responses are dampened or obliterated.

ii. Introduction of a Human Graft

It is not intended that the present invention be limited to the methodby which a human graft is introduced into an animal host. In a preferredembodiment, however, a transcutaneous incision is made into the dorsalaspect of a vertebrate host animal. In one example, said incision ismade with scissors. In another example said incision is made with atrochar. In another example said incision is made with a scalpel.Through this incision a free space is developed between the dermis andthe super muscular facia sufficient to accommodate a human vaginaltissue graft comprising a lumen substantially lined with epithelium.

In one embodiment, the opening to the lumen of said subdermallyimplanted vaginal tissue graft is approximated to the edge of theincision of said animal host. In this embodiment, the opening to thelumen of said implanted vaginal tissue is in fluidic communication withthe environment outside the animal. In another embodiment, the openingof the lumen (in fluidic communication with the atmosphere) to saidvaginal tissue graft is maintained with a stent. In one embodiment, saidsubcutaneous implanted vaginal tissue graft with a patent lumen issealed at one end, thereby creating a blind lumen. In another embodimentsaid subcutaneous implanted vaginal tissue graft with an open lumen iscompletely advanced into the subcutaneous space and the above referencedtranscutaneous incision is closed, thereby sealing said tissue graftinto said subdermal space.

B. Graft Maintenance

The vaginal epithelium provides the primary barrier against infection bypathogens introduced into the vagina. The normal morphology andphysiology of the human vaginal epithelium, however, is responsive tomodulations (associated with the menstrual cycle) of various trophicfactors which include, but are not limited to, steroid hormones. Forexample, the vaginal epithelium tends to thicken in an estrogen richenvironment while it may thin in a progesterone rich environment. Whileit is not essential to provide supplementation of gonadal hormones topractice the instant invention, in preferred embodiments, the non-humanhost is supplemented with one or more gonadal hormones at dosages whichcause the engrafted tissue to present a morphology similar to thatobserved within in situ vaginal tissue during a given phase of the humanmenstrual cycle including, but not limited to, the follicular phase andthe luteal phase.

Engrafting xenografts in the presence of estrogen and/or progesterone(at levels comparable to clinical values for these hormones) isdesirable. While it is not intended that the present invention belimited to supplementation of gonadal hormones at any specific, FIG. 5presents illustrative values of mean estrogen and progesterone levels atvarious stages of the menstrual cycle (cycle stage of hormonalresponsiveness may alter susceptibility/resistance to STDs).Additionally, there are increasing numbers of women worldwide who uselong-term steroid based birth control that sustain circulating levels ofgonadal steroid hormones.

The hormonal supplementation of a non-human host, therefore, mayrecapitulate the morphology and physiology of engrafted vaginalxenografts at various phases of the human menstrual cycle or a menstrualcycle regulated by steroid contraceptives. Therefore, the presentinvention permits the evaluation of the efficacy of potentialmicrobicides in vaginal xenografts which have been hormonally induced tomimic, morphologically and physiologically, equivalent in situ vaginaltissue at various stages of the menstrual cycle.

In one embodiment, the non-human host is supplemented with an estrogen.In a preferred embodiment, said estrogen is β-estradiol. In anotherembodiment, the host animal is supplemented with progesterone.Combination hormonal treatments are also contemplated.

i. Delivery Of Supplemental Hormones

As recited above, the supplementation of a non-human host with hormones(or other trophic factors) is not a prerequisite to practicing theinstant invention. However, in those embodiments where said non-humanhost is supplemented with hormones or trophic factors, it is notintended that the present invention be limited to a specific deliverysystem. In one embodiment the delivery system is an osmotic pump. In apreferred embodiment the delivery system is silastic tubing. SilasticBrand Medical Adhesive Silicone Type A, Dow Corning (Midland, Mich.).

While it is not intended the present invention be limited to anyspecific formulation or dimension of silastic tubing, in one embodimentsaid silastic tubing was fabricated according to the following method.Tubing (0.078 in. inner diameter by 0.125 in. outer diameter; DowCorning, Midland, Mich.) was filled with 17β-estradiol (1,3,5[10]-Estratriene-3, 17β) (Sigma Chemical Company, St. Louis, Mo.) mixed1:3 (w/w) with silastic 382 medical grade elastomer (Dow Coming, St.Louis, Mo.). The mixture was allowed to dry and the tubing cut, in oneembodiment, to a size (approximately 2×2×1 mm) which yielded ameasurable circulating estradiol concentration of about 150-200 pg/ml inmice. It may be noted that this concentration of estradiol approximatesthe concentration of estrogen in women during the late follicular phaseof the menstrual cycle.

C. Graft Manipulation

The above referenced human vaginal xenografts may be translocated to avariety of spaces in a non-human host. It is not intended that thepresent invention be limited to a specific location. In one embodiment,the space is the peritoneum. In another embodiment the thoracic cavityis contemplated. In another embodiment, the renal capsule iscontemplated. In another embodiment the anterior chamber of the eye iscontemplated. In another embodiment the brain is contemplated. In apreferred embodiment, the subcutaneous space is contemplated. Morespecifically, the subdermal space of the dorsal aspect of a non-humanvertebrate including (but not limited to) an immunocompromised mouse. Inone example of said preferred subdermal environment, the opening of thepatent lumen of a rolled human vaginal xenograft is approximated to theskin such that said lumen may be directly accessed without additionaldissection. In another example of said preferred subdermal environment,said rolled human vaginal xenograft (with a patent lumen) issubstantially sealed when implanted into the subdermal space. In thisexample said non-human host may be briefly anesthetized so that saidrolled human vaginal xenograft may be manipulated through atranscutaneous incision. It is not intended that the present inventionbe limited to the instrument to make said transcutaneous incision. Inone example the instrument is a scalpel. In another example theinstrument is a scissor. Additionally, it is not intended the presentinvention be limited by the instrumentation used to introduce materialsor agents into the lumen of said human vaginal xenografts. In oneexample said introducing instrument is a plastic pipet. In anotherexample said introducing instrument is a glass pipet. In another examplesaid introducing instrument is a trochar. In another example saidintroducing agent is a swab.

D. Cytochemical Characterization of the Vaginal Wall in EstablishedXenografts

The engrafted xenobiotic tissue recited in the instant inventionsubstantially recapitulates the morphology and physiology of normalhuman tissue observed in situ. This fidelity to normal form and functionis confirmed by examining the phenotype of the xenobiotic experimentalplatform with respect to various facets of normal cellular expression.Specifically, said xenobiotic engrafted human vaginal tissue expressesglycogen, estrogen receptor (ER), progesterone receptor (PR), and geneproducts tangent to the ability of vaginal epithelium to defend againstinvasion by pathogens (or against environmental damage related tophysical and chemical stressors) at levels comparable to ungraftedcontrols.

i. Glycogen, ER and PR: Products Known to be Involved in HormonalResponsiveness of the Tissue

A stratified squamous epithelium and glycogen production are estrogendependent characteristics of normal human vaginal morphology andphysiology essential for the control of pathogens in the vagina. Aspresented in FIG. 2, glycogen, ER and PR of vaginal xenografts engraftedin estrogenized mice parallel the topography and cellular localization,as compared sections removed from in situ normal premenopausal vagina,of these identical parameters.

Specifically samples, from histological sections of human vaginalxenografts engrafted in an immunocompromised mouse for at least 14 days,were prepared according to the following protocols. Sections (8 um) werecut from formalin fixed, paraffin embedded tissue. Specificity ofPeriodic Acid Schiff (PAS) stain for glycogen was demonstrated byabsence of staining in sections subjected to amylase digestion.Immunocytochemistry for ER and PR was carried out following antigenretrieval (steam heating for 20 min. in citrate buffer pH 6.0) usingalkaline phosphatase as reporter, bromo-chloro-indolyl phosphate assubstrate and nitro-blue tetrazolium as chromogen. Specificity of ER andPR immunoreactions were confirmed by absence of reaction product insections exposed to secondary antibodies only or to primary antibodiespreabsorbed with excess ER and PR antigen, respectively (not shown).Findings were replicated using two different antibodies for eachreceptor.

Data from these above referenced histological preparations show thatamylase sensitive glycogen is present in cell cytoplasm as revealed byPAS stain. Glycogen is localized in differentiated, superficialepithelial cells and in desquamating “dead” cells with pyknotic nuclei.ER and PR are localized to the cytoplasm and showed more intensestaining in the more immature cells of the epithelium. Immunostainingfor ER and PR is limited to cells in the basal and parabasal layers,consistent with histological surveys of normal vaginal tissue asreported by Hodgins et al., “An immunohistochemical study of androgen,oestrogen and progesterone receptors in the vulva and vagina.” Br. J.Obstet. Gyn. 105:216-222, (1998). Furthermore, ER immunostaining wasobserved in both cytoplasm and in nuclei (FIG. 1, ×100, N and C) whilePR staining is mostly confined to the cytoplasm.

ii. Gene Products Produced in the Vagina

Tissues, such as the vagina, are equipped with an armamentarium ofdefenses against invasion by pathogens and against damage byenvironmental stressors. In order to demonstrate parity in form andfunction of the xenobiotic engrafted human vaginal tissue, which is acomponent of the screening method claimed in the instant invention, toin situ vaginal tissue; a number of gene products were compared.

Specifically, normal sections from in situ human vagina and sectionsfrom vaginal xenografts engrafted into mice have been examined for twogene products liberated or secreted into the vaginal lumen. These geneproducts include LF and surfactant protein A (SP-A).

LF binds and, thereby, limits availability of free iron (Fe) in tissuesand body fluids. LF is a significant marker because Fe is needed bycertain cellular pathogens for replication. While the instant inventionis not limited to a specific mechanism, vaginal LF exerts abacteriostatic function that is a useful marker for factors contributingto the preservation of a normal vaginal milieu.

Similarly, SP-A contributes to host defenses by facilitatingphagocytosis, recruiting cells in the monocyte/macrophage lineage,thereby enhancing the immune response. Wright, J. R., et al., “Plumonarysurfactant protein A stimulates chemotaxis of alveolar macrophage.” Am.J. Physiol. 264:(4 Pt 1) L338-344 (1993). As seen in FIG. 3 thedistribution of immunoreactive SP-A is the same in normal vagina ascompared to xenografts. Specifically, immunoreactive SP-A is seen in thedifferentiated and desquamated cell layer with localization identical toglycogen. This observation once again supports the structural andfunctional parity between the xenobiotic screening platform as claimedin the instant invention and normal post menopausal vaginal tissueobserved in situ.

Additionally, as presented in FIG. 3, several other gene products showcomparable expression between vaginal xenografts and control specimensremoved from in situ vagina. Specifically, catalase, glutamyl cysteinesynthase (GCS), Mn and Cu/Zn superoxide dismutases (SOD) andglutathione-S-transferase (GST). That is to say the photomicrographs ofsections of premenopausal vaginal tissue, in FIG. 3, present controls(C) and vaginal xenografts (X) showing localization of immunoreactivelactoferrin, surfactant protein A (SP-A), catalase and Cu/ZN superoxidedismutase (SOD) which are selected markers of host defenses. TheJunction between basal epithelial cells and stroma is indicated by solidblack lines.

II. Application Of Candidate Antimicrobial Compounds

It is not intended that the present invention be limited to a specificprotocol to administer a candidate microbicide. In one embodiment, thecandidate microbicide is mixed with a given pathogen in vitro and saidmixture is subsequently introduced into lumen of the engrafted humanxenograft disposed within a non-human host. In another embodiment, thecandidate microbicide is pre-administered to the engrafted human vaginallumen before the delivery of pathogens to said human vaginal lumen. Inyet another embodiment, the microbicide is administered systemically andthe pathogen is introduced into the lumen of the xenograft.

III. Infection Of Human Vaginal Xenografts With Pathogens

While it is not intended the screening method recited in the instantinvention be limited to a specific group of pathogens, Table 2 presentsexamples of pathogenic agents in the screening methods recited in theinstant invention. The pathology resulting from infection of xenograftswith said pathogens recapitulates the pathology of the disease stateobserved from sections of in situ vagina inflected with said pathogens.This fidelity to human pathological processed provides for the screeningof candidate antimicrobials within said susceptible xenografts. That isto say, xenografts exposed to pathogens may be qualitatively orquantitative evaluated to determine whether infected tissues recover orif infections are blocked altogether.

PAPILLOMA VIRUSES Bovine papillomavirus (BPV-1) BPV-4 Cottontail rabbitpapillomavirus (CRPV) HPV-1 HPV-5 HPV-11 HPV-40 LVX82/MM7 POXVIRUSESMolluscum contagiosum HERPESVIRUSES HSV-2 Varicella zoster virus OTHERSVaccinia virus Norwalk agent

A. Inoculation of Xenografts with Pathogens

The human vaginal xenografts recited in the instant invention areobtained as specimens from surgical procedures or at autopsy, and may beprepared according to conventional techniques. In a preferredembodiment, said vaginal xenograft comprises a split-thickness graft. Inone embodiment, said split thickness grafts are prepared in asubstantially aseptic environment under conditions such that transplantviability in a non-human host is maximized. In one embodiment, saidviability maximizing condition comprises maintaining said grafts in aculture medium (including but not limited to Minimum Essential Medium)prior to transplant. In a preferred embodiment said viability maximizingcondition comprises maintaining said grafts in a culture medium(including but not limited to Minimum Essential Medium) supplementedwith antibiotic to prevent subsequent bacterial infection and to controlany endogenous bacterial infection in the graft.

In one embodiment a rolled split thickness human vaginal xenograft hasengrafted within a host for a period of time. Preferably, said engravingtime is between approximately two and approximately fourteen days. Mostpreferably said engrafting time is greater than fourteen days.Subsequent to said engrafting, a given pathogen is introduced into thelumen of said engrafted rolled split thickness xenograft. Suitableinstruments for the introduction of said pathogens into the lumen ofsaid split thickness xenograft include (but are not limited to) pipettips, syringes and swabs.

In one embodiment, the lumen of a rolled split thickness human vaginalxenograft is inoculated with a given pathogen prior to the introductionof said inoculated xenograft into a host. Said inoculated rolled splitthickness human xenograft is subsequently implanted into a host andallowed to engraft. Said inoculated engrafted tissue is permitted toremain for a period sufficient for the pathogen to multiply and arecoverable quantity of said pathogens may be produced. The graftedtissue itself may grow, become morphologically transformed, or otherwisechange.

In the case of HPV, the xenograft becomes transformed by the virus. Thevirus grows in the xenograft in sufficient quantities for recovery inapproximately 3 to 5 months after the transplantation.

IV. Detecting Pathogens In Pathogen Inoculated Human Vaginal Xenografts

Detecting residual infectivity and pathogen infiltration into the abovecaptioned xenografts is a facet of the screening methods for candidateantimicrobial compounds contemplated by the instant invention. Thepresent invention contemplates a variety of protocols to determine if acandidate antimicrobial compound exerts a microbicidal effect asevidenced by an absent (or diminished) residual infectivity in thepathogen inoculated grafts recited above.

In one embodiment, the polymerase chain reaction (PCR) is a protocolused to evaluate residual infectivity. PCR refers to the method of K. B.Mullis U.S. Pat. Nos. 4,683,195 and 4,683,202, hereby incorporated byreference, which describe a method for increasing the concentration of asegment of a target sequence in a mixture of genomic DNA without cloningor purification. This process for amplifying the target sequenceconsists of introducing a large excess of two oligonucleotide primers tothe DNA mixture containing the desired target sequence, followed by aprecise sequence of thermal cycling in the presence of a DNA polymerase.The two primers are complementary to their respective strands of thedouble stranded target sequence. To effect amplification, the mixture isdenatured and the primers then annealed to their complementary sequenceswithin the target molecule. Following annealing, the primers areextended with a polymerase so as to form a new pair of complementarystrands. The steps of denaturation, primer annealing and polymeraseextension can be repeated many times (i.e., denaturation, annealing andextension constitute one “cycle”; there can be numerous “cycles”) toobtain a high concentration of an amplified segment of the desiredtarget sequence. The length of the amplified segment of the desiredtarget sequence is determined by the relative positions of the primerswith respect to each other, and therefore, this length is a controllableparameter. By virtue of the repeating aspect of the process, the methodis referred to as the “polymerase chain reaction” (hereinafter “PCR”).Because the desired amplified segments of the target sequence become thepredominant sequences (in terms of concentration) in the mixture, theyare said to be “PCR amplified”. With PCR, it is possible to amplify asingle copy of a specific target sequence in genomic DNA to a leveldetectable by several different methodologies (e.g., hybridization witha labeled probe; incorporation of biotinylated primers followed byavidin-enzyme conjugate detection; incorporation of ³²P-labeleddeoxynucleotide triphosphates, such as dCTP or dATP, into the amplifiedsegment). In addition to genomic DNA, any oligonucleotide sequence canbe amplified with the appropriate set of primer molecules. Inparticular, the amplified segments created by the PCR process itselfare, themselves, efficient templates for subsequent PCR amplifications.In this way, the presence of even a minute amount of DNA or RNA from agiven pathogen, within a given pathogen inoculated human vaginalxenograft, may be documented

In another embodiment in situ hybridization is a protocol used toevaluate residual infectivity. In this procedure, radioactive nucleicacid probes are hybridized with preparations of fixed cells rather thanwith purified DNA. In this way chromosomal sites of DNA or RNA ofinterest (e.g. pathogenic DNA or RNA ) may be directly visualized bystandard microscopic techniques.

In another embodiment, gel electrophoresis provides protocols used toevaluate residual infectivity. In this procedure, an extract from saidinoculated human vaginal xenografts may be placed at the top of a tubeor other system containing a matrix (made of polyacrylamide) andsubjected to an electrical field. The rate of migration of amacromolecule (e.g., pathogen proteins) through the matrix producescharacteristic bands which may be used as an index for pathogenicprotein synthetic activity and, thereby, residual infectivity.

In another embodiment, immunocytochemical protocols are used to detectresidual infectivity. In this method, cells are fixed briefly withalcohol (to immobilize their contents) and then treated with acetone andair-dried to disrupt plasma membranes, thereby rendering the interior ofsuch permeabilized cells accessible to large molecules. In oneembodiment, said fixed permeabilized cells may be reacted with aflorescent conjugated antibody specific for a given pathogenic protein.In this way infection of said pathogen inoculated vaginal epithelium maybe documented.

EXPERIMENTAL

The following examples are provided in order to demonstrate and furtherillustrate certain preferred embodiments and aspects of the presentinvention and are not to be construed as limiting the scope thereof.Although embodiments have been described with some particularity, manymodifications and variations of the preferred embodiment are possiblewithout deviating from the invention.

EXAMPLE 1

Propagation of Sexually Transmitted Fastidious Viral Pathogens

This example describes the propagation of fastidious viral pathogens.While the propagation methods recited in this example may be applied toa variety of fastidious viruses, in this example said fastidious virusis HPV. HPV is derived from infected tissue known to have detectableamounts of virus to produce an extract with a sufficient titer (numberor concentration of infectious virions) to infect a susceptible tissue.Specifically, human genital epithelial tissue (including the cervix) orvulvar condylomata acuminata (infected with HPV's) are preferred. Vulvarcondylomata were obtained from 15 female patients and stored at −70° C.until used. A total of 20 g was thawed, minced with scissors, anddisrupted in 50 ml of PBS at 4° C. with a Virtis homogenizer at 25,000rpm for 30 minutes. Cell-free supernatants and pellets were obtained bysedimentation at 1,000×g, separated, and stored at −70° C. Thesupernatant was used without further dilution to infect vaginalxenografts. However, those skilled in the art will be able to adjust thetiter of the above referenced supernatant to present an extract with asufficient viral load to infect the human xenograft recited in theinstant invention.

EXAMPLE 2

Construction of Split-Thickness Rolled Grafts

In this example, split thickness xenografts of human vagina are preparedaccording to the following method. Split thickness vaginal wallspecimens were obtained from surgical sources. Vaginal wall specimensfrom any source were subjected to both gross and microscopic examinationto confirm that said specimens were free from detectable lesions.Split-thickness grafts were created by cutting said vaginal wallspecimens with a sterile double-edged razor blade clamped in a curvedKelly hemostat. Grafts were held in culture medium with only gentamicin(800 micrograms per milliliter) as supplement, and were subsequentlytrimmed to dimensions of 2 cm×2 cm×0.5 mm. Said trimmed tissue was thenrolled such that an open lumen was created wherein the internal diameterof said lumen is lined with vaginal epithelium.

EXAMPLE 3

Screening of Candidate Microbicides in Vaginal Xenografts Infected withHPV

In this example, human vaginal xenografts were infected with HPV byinoculating the lumen of said vaginal xenografts, engrafted into anon-human host, with HPV-11 stock virus suspensions prepared accordingto the methods presented in Example 1. Experiments (data not shown) havedemonstrate that even a 1:1000 dilution of said viral stock producedinfections at an incidence greater than 90% in inoculated susceptibletissue. Furthermore, it is not necessary to traumatize the walls of saidgrafts during inoculation to precipitate infection.

In experimental samples, candidate microbicides are mixed with HPV invitro prior to administration of said HPV/candidate microbicide mixtureto the lumen of a vaginal xenograft engrafted into a non-human host. Inan alternative experimental embodiment, candidate microbicides werepre-administered to the vaginal lumen, before delivery of a pathogenicagent, into the same lumen.

Xenografts are harvested at 70-90 days and are screened for signs ofvirus replication. Said screening protocols include quantification ofmorphologic transformations, viral DNA and RNA synthesis, and proteinsynthesis. In addition, cell-free extracts of infected xenografts aretested by bioassay for the presence of infectious virus using standardprocedures for infection and transformation of vaginal epithelium.

EXAMPLE 4

Screening of Candidate Microbicides in Vaginal Xenografts Infected withHIV

In this example, human vaginal xenografts are infected with HIV byinoculating the lumen of said vaginal xenografts, engrafted into anon-human host, with HIV stock virus suspensions. HIV viral strainstested include lymphocytotrophic strains, HIV-1 strain III B and MN, andmonocytotrophic strains Bal and ADA, as well as dual trophic strain89.6. Virus preparations may be obtained from commercial sourcesincluding Advanced Biotechnologies (Rockville, Md.).

In experimental samples, candidate microbicides are mixed with HIV invitro prior to administration of said HIV/candidate microbicide mixtureto the lumen of an vaginal xenograft engrafted into a non-human host. Inan alternative embodiment, candidate microbicides are pre-administeredto the vaginal lumen prior to delivery of HIV suspensions into the samelumen.

Xenografts are harvested at different intervals and assayed for virusmacromolecules and virus yield, according to methods well known in theart, to determine if HIV infection has occurred.

EXAMPLE 5

Screening of Candidate Microbicides in Vaginal Xenografts Infected withHIV Infected Cells

Purified viral suspensions of HIV may also be used to initiateinfections of cells in culture and these infected cells are thentransferred into the lumen of vaginal xenografts engrafted into anon-human host.

For the lymphocytotrophic strains of HIV, infections are initiated inSUP T or JURKAT cells. Smith, S. D., et al., “Monoclonal antibody andenzymatic profiles of human malignant T-lymphoid cells and derived celllines.”, Cancer Res. 44:5657-5660 (1984), Gillis, S., et al.,“Biochemical and biological characterization of lymphocyte regulatorymolecules. V. Identification of an interleukin 2-producing humanleukemia T cell line.” J. Exp. Med. 152:1709-1719 (1980). Formonocytotrophic strains HIV, infections are initiated in THP-1 or U937cells. Tsuchiya, S., et. al., “Establishment and characterization of ahuman acute monocytic leukemia cell line (THP-1).” Int. J. Cancer26:171-176 (1980), Sundstrom, C., et al., “Establishment andcharacterization of a human histiocytic lymphoma cell line (U937).” Int.J. Cancer 17:565-577 (1976). Additionally, infections with one or bothtypes of HIV strains are initiated in peripheral blood leukocytes. Ineach scenario, the above referenced in vitro HIV infected cells aremonitored for the synthesis of new HIV progeny.

At times, corresponding to a peak of virus replication in said in vitroHIV inoculated cells, infected cells are transferred to the xenografts.The fate of the inoculated cells are evaluated histologically for thepresence of viable lymphoreticular cells.

In experimental samples, candidate microbicides are mixed with said HIVinoculated cells in vitro prior to administration of said HIV inoculatedcell/candidate microbicide mixture to the lumen of a vaginal xenograftengrafted into a non-human host. In an alternative embodiment, candidatemicrobicides are pre-administered to the vaginal lumen, before deliveryof said HIV inoculated cells, into the same lumen.

EXAMPLE 6

Screening of Candidate Microbicides in Vaginal Xenografts Inoculatedwith C. Trachomatis

In this example, human vaginal xenografts are infected with C.trachomatis by inoculating the lumen of said vaginal xenografts,engrafted into a non-human host, with a culture of C. trachomatis.

In experimental samples, candidate microbicides are mixed with C.Trachomatis in vitro prior to administration of said C.trachomatis/candidate microbicide mixture to the lumen of a vaginalxenograft engrafted into a non-human host. In an alternative embodiment,candidate microbicides are pre-administered to the vaginal lumen, beforedelivery of a culture of C. trachomatis, into the same lumen.

Quantitation of C. trachomatis survival following microbicide exposureis accomplished by in vitro assay of C. trachomatis survival inxenograft lavages or extracts.

EXAMPLE 7

Use of Sodium Dodecyl Sulfate (SDS) as a Candidate Microbicide in theInstant Screening System

In this example, human vaginal xenografts engrafted for ten days in thesubcutaneous space of an immunocompromised mouse were infected with 10ul of HPV-11, or HPV-11 that had been treated with 0.05% SDS at 37° C.for 10 minutes and then placed in the lumen of the grafts. At varyingintervals, the infected human xenografts (or portions thereof) weresurgically removed and examined. These infected tissues exhibitedpapillomatous transformations with the elaboration of abundant virus DNAand virus protein demonstrating virion production.

This pathological morphology and physiology was not seen in tissuesreceiving SDS-treated virus and these samples exhibited stratifiedsquamous epithelium with a morphology analogous to normal in situvagina. Indeed, as illustrated in FIG. 4 the SDS effectively preventedvirus infection but did not kill the treated epithelium in the vaginalxenograft.

EXAMPLE 8

Assay of Xenografts for Infection by Pathogens

The human vaginal xenografts recited in the instant invention may berecovered and assayed for pathogenic infection any time after theinoculation of pathogens. Recovery may be effected by sacrificing theanimal and removing the tissue, from which the pathogen may be extractedby known techniques. Alternatively, the virus may be recovered while thetissue remains in the living animal through known techniques, such assurgical removal of part or all of the xenograft tissue.

It is not intended the present invention be limited to a specific assayor technique to evaluate whether a human vaginal xenograft has beeninfected with a given pathogen. There are a number of standard culturetechniques for infectivity, including but not limited to, quantitativecolony culture on agar plates (for bacteria) and quantitative plaqueassays (for viruses).

In one embodiment (where the pathogen contacted to said vaginalxenograft is a virus) the tissue is homogenized, said homogenate issubjected to centrifugation using cesium chloride density gradients tocause sedimentation of the virus particles. Under these conditions,viral particle localize as a homogeneous band or bands at thosedensities which correspond to its buoyant density. In the example of HPVthis is at approximately 1.34 g/cc and slightly above.

In another embodiment, said pathogen assay technique is PCR. In anotherembodiment, said pathogen assay technique is in situ hybridization. Inanother embodiment said pathogen assay technique is protein staining. Inanother embodiment, said pathogen assay technique is gelelectrophoresis. In another embodiment, said pathogen assay technique isimmunocytochemistry.

From the above, it is clear the present invention provides compositionsand methods for the screening of candidate microbicides. In particular,the present invention provides a human vaginal xenograft, engrafted intoa non-human host, as a platform for screening the efficacy of topicallyapplied candidate antimicrobial agents against pathogens of interestincluding (but not limited to) HSV-2, HPV, HIV, and C. trachomatis.

All publications and patents mentioned in the above specification areherein incorporated by reference. Although the invention has beendescribed in connection with specific preferred embodiments, it shouldbe understood that the invention as claimed should not be limited tosuch specific embodiments. Indeed, various modifications of thedescribed modes for carrying out the invention which are obvious tothose skilled in the art are intended to be within the scope of thefollowing claims.

What is claimed is:
 1. A composition comprising a vaginal graftcomprising isolated human vaginal tissue configured so as to comprise alumen substantially lined with epithelial cells wherein said vaginalgraft is engrafted into an immunocompromised non-human host.
 2. Thecomposition of claim 1, wherein said vaginal tissue comprises splitthickness vaginal tissue.
 3. The composition of claim 1, wherein saidvaginal graft is infected with a pathogen.
 4. The composition of claim3, wherein said pathogen is selected from the group of consisting ofbacteria, fungi, and viruses.
 5. The composition of claim 4, whereinsaid viruses are selected from the group consisting of HSV-2, HPV, andHIV.
 6. The composition of claim 1, wherein said vaginal graft has beenexposed to one or more gonadal hormones.
 7. The composition of claim 6,wherein said hormone is selected from the group consisting ofβ-estradiol and progesterone.